Cargando…
Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases: Insights From Pulmonary Arterial Hypertension
BACKGROUND: Conducting randomized controlled trials to investigate survival in a rare disease like pulmonary arterial hypertension has considerable ethical and logistical constraints. In many studies, such as the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Impr...
Autores principales: | Torbicki, Adam, Bacchi, Marisa, Delcroix, Marion, Farber, Harrison W., Ghofrani, Hossein-Ardeschir, Hennessy, Brian, Jansa, Pavel, Mehta, Sanjay, Perchenet, Loïc, Pulido, Tomas, Rosenberg, Daniel, Rubin, Lewis J., Sastry, B.K.S., Simonneau, Gérald, Sitbon, Olivier, Souza, Rogério, Wei, Lee-Jen, Channick, Richard, Benza, Raymond |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665498/ https://www.ncbi.nlm.nih.gov/pubmed/31109190 http://dx.doi.org/10.1161/CIRCOUTCOMES.118.005095 |
Ejemplares similares
-
Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN
por: Simonneau, Gérald, et al.
Publicado: (2015) -
SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2017) -
Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial
por: Souza, Rogério, et al.
Publicado: (2018) -
Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension
por: Souza, Rogério, et al.
Publicado: (2022) -
Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study
por: Chin, Kelly M., et al.
Publicado: (2019)